Conatus Accepts Defeat For Emricasan In NASH

 
• By Joseph Haas

After multiple Phase IIb trial failures, Conatus says it will fulfill contractual obligations and consider strategic alternatives. Partner Novartis was already focused on other candidates and partnerships in NASH.

Silhouette of an exhausted sportsman at sunset with the horizon in the background - Image
Conatus' long struggle with emricasan is at an end

More from Clinical Trials

More from R&D